Raschi, E <br/><br/>
Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems.  [electronic resource] 

 -  Nutrition, metabolism, and cardiovascular diseases : NMCD  06 2018 
 - 533-542 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1590-3729 
<br/><br/><label>Standard No.: </label>10.1016/j.numecd.2018.02.014  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adverse Drug Reaction Reporting Systems<br/>Clinical Decision-Making<br/>Diabetes Mellitus, Type 2--diagnosis<br/>Humans<br/>Patient Selection<br/>Pharmacovigilance<br/>Risk Assessment<br/>Risk Factors<br/>Sodium-Glucose Transporter 2 Inhibitors--adverse effects<br/>Treatment Outcome